| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Child Development Disorders, Pervasive | 68 | 2015 | 615 | 10.520 |
Why?
|
| Autistic Disorder | 87 | 2024 | 1185 | 8.490 |
Why?
|
| Antipsychotic Agents | 72 | 2022 | 3057 | 4.190 |
Why?
|
| Risperidone | 49 | 2016 | 383 | 4.170 |
Why?
|
| Williams Syndrome | 8 | 2024 | 187 | 3.900 |
Why?
|
| Obsessive-Compulsive Disorder | 57 | 2021 | 1444 | 3.600 |
Why?
|
| Psychotropic Drugs | 13 | 2021 | 894 | 2.910 |
Why?
|
| Angelman Syndrome | 6 | 2023 | 136 | 2.610 |
Why?
|
| Irritable Mood | 17 | 2021 | 183 | 2.470 |
Why?
|
| Fragile X Syndrome | 7 | 2014 | 115 | 2.200 |
Why?
|
| Social Behavior | 19 | 2021 | 1127 | 1.940 |
Why?
|
| Guanfacine | 9 | 2024 | 51 | 1.940 |
Why?
|
| Taurine | 5 | 2014 | 94 | 1.790 |
Why?
|
| Clozapine | 7 | 2023 | 498 | 1.710 |
Why?
|
| Excitatory Amino Acid Antagonists | 7 | 2011 | 449 | 1.680 |
Why?
|
| Buspirone | 9 | 2024 | 82 | 1.660 |
Why?
|
| Tics | 3 | 2023 | 70 | 1.640 |
Why?
|
| Aggression | 22 | 2023 | 753 | 1.540 |
Why?
|
| Asperger Syndrome | 9 | 2012 | 63 | 1.500 |
Why?
|
| Anti-Anxiety Agents | 5 | 2024 | 390 | 1.430 |
Why?
|
| Catatonia | 2 | 2023 | 158 | 1.420 |
Why?
|
| Quinolones | 9 | 2014 | 367 | 1.400 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 19 | 2024 | 3658 | 1.330 |
Why?
|
| Central Nervous System Stimulants | 14 | 2022 | 1148 | 1.320 |
Why?
|
| Child | 154 | 2024 | 77709 | 1.310 |
Why?
|
| Psychiatric Status Rating Scales | 52 | 2021 | 6038 | 1.300 |
Why?
|
| Piperazines | 17 | 2015 | 2488 | 1.290 |
Why?
|
| Interpersonal Relations | 8 | 2020 | 1425 | 1.240 |
Why?
|
| Serotonin Antagonists | 11 | 2002 | 144 | 1.220 |
Why?
|
| Serotonin | 24 | 2019 | 1017 | 1.200 |
Why?
|
| Isoxazoles | 5 | 2013 | 216 | 1.190 |
Why?
|
| Psychopharmacology | 3 | 2021 | 143 | 1.130 |
Why?
|
| Down Syndrome | 5 | 2024 | 880 | 1.090 |
Why?
|
| Adolescent | 135 | 2024 | 85781 | 1.090 |
Why?
|
| Stereotyped Behavior | 10 | 2023 | 136 | 1.040 |
Why?
|
| Tryptophan | 19 | 2004 | 478 | 1.020 |
Why?
|
| Adrenergic alpha-Agonists | 8 | 2010 | 177 | 1.010 |
Why?
|
| Central Nervous System Agents | 2 | 2018 | 72 | 0.990 |
Why?
|
| Memantine | 3 | 2011 | 100 | 0.980 |
Why?
|
| Communication Disorders | 3 | 2017 | 51 | 0.950 |
Why?
|
| Psychomotor Agitation | 5 | 2020 | 293 | 0.940 |
Why?
|
| Weight Gain | 17 | 2016 | 2292 | 0.940 |
Why?
|
| Child, Preschool | 86 | 2022 | 41006 | 0.910 |
Why?
|
| Stereotypic Movement Disorder | 3 | 2021 | 29 | 0.910 |
Why?
|
| Methylphenidate | 9 | 2016 | 473 | 0.890 |
Why?
|
| Fluvoxamine | 16 | 1999 | 74 | 0.870 |
Why?
|
| Humans | 321 | 2024 | 744343 | 0.820 |
Why?
|
| Social Behavior Disorders | 4 | 2011 | 97 | 0.790 |
Why?
|
| Riluzole | 2 | 2011 | 55 | 0.770 |
Why?
|
| Double-Blind Method | 61 | 2024 | 12026 | 0.760 |
Why?
|
| Self-Injurious Behavior | 10 | 2015 | 465 | 0.750 |
Why?
|
| Trichotillomania | 6 | 2005 | 172 | 0.740 |
Why?
|
| Autoimmune Diseases | 5 | 2021 | 2133 | 0.740 |
Why?
|
| Dopamine Antagonists | 9 | 2010 | 296 | 0.740 |
Why?
|
| Pilot Projects | 27 | 2022 | 8324 | 0.740 |
Why?
|
| Pirenzepine | 5 | 2001 | 115 | 0.710 |
Why?
|
| Mental Disorders | 10 | 2021 | 6600 | 0.710 |
Why?
|
| Prenatal Exposure Delayed Effects | 7 | 2024 | 2408 | 0.670 |
Why?
|
| Male | 209 | 2023 | 350118 | 0.660 |
Why?
|
| Conversion Disorder | 1 | 2021 | 205 | 0.640 |
Why?
|
| Dystonia | 1 | 2020 | 363 | 0.580 |
Why?
|
| Comorbidity | 22 | 2022 | 10388 | 0.570 |
Why?
|
| Child Language | 1 | 2017 | 64 | 0.570 |
Why?
|
| Female | 181 | 2024 | 380194 | 0.550 |
Why?
|
| Treatment Outcome | 60 | 2024 | 63114 | 0.550 |
Why?
|
| Anxiety Disorders | 9 | 2024 | 2690 | 0.550 |
Why?
|
| Acetylcysteine | 2 | 2016 | 272 | 0.550 |
Why?
|
| Vitamin B Complex | 2 | 2020 | 288 | 0.540 |
Why?
|
| Thiazoles | 5 | 2015 | 1483 | 0.530 |
Why?
|
| Oxytocin | 9 | 2023 | 394 | 0.510 |
Why?
|
| Cycloserine | 3 | 2017 | 113 | 0.510 |
Why?
|
| Brain | 21 | 2023 | 26385 | 0.500 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2015 | 87 | 0.500 |
Why?
|
| Psychotic Disorders | 5 | 2021 | 3046 | 0.490 |
Why?
|
| Behavior Therapy | 9 | 2023 | 865 | 0.490 |
Why?
|
| Sleep | 7 | 2020 | 4623 | 0.490 |
Why?
|
| Psychological Theory | 1 | 2015 | 168 | 0.480 |
Why?
|
| Intelligence | 4 | 2016 | 920 | 0.470 |
Why?
|
| Dose-Response Relationship, Drug | 26 | 2024 | 10943 | 0.470 |
Why?
|
| Nootropic Agents | 1 | 2015 | 160 | 0.460 |
Why?
|
| Parents | 14 | 2021 | 3407 | 0.460 |
Why?
|
| Motor Skills | 1 | 2017 | 522 | 0.460 |
Why?
|
| Dibenzothiazepines | 3 | 2008 | 103 | 0.460 |
Why?
|
| Epilepsy | 5 | 2024 | 3310 | 0.450 |
Why?
|
| Sensation Disorders | 1 | 2014 | 155 | 0.440 |
Why?
|
| Fructose | 1 | 2015 | 288 | 0.440 |
Why?
|
| Clomipramine | 10 | 2001 | 54 | 0.440 |
Why?
|
| Adult | 117 | 2023 | 214055 | 0.440 |
Why?
|
| Occupational Therapy | 1 | 2014 | 134 | 0.430 |
Why?
|
| Anxiety | 15 | 2024 | 4297 | 0.430 |
Why?
|
| Bruxism | 1 | 2011 | 15 | 0.420 |
Why?
|
| Longevity | 1 | 2020 | 1070 | 0.420 |
Why?
|
| Sex Characteristics | 3 | 2019 | 2585 | 0.420 |
Why?
|
| Fluoxetine | 10 | 1999 | 749 | 0.420 |
Why?
|
| GABA Antagonists | 1 | 2011 | 128 | 0.400 |
Why?
|
| Antidepressive Agents, Tricyclic | 4 | 2001 | 434 | 0.400 |
Why?
|
| Tic Disorders | 9 | 1999 | 127 | 0.400 |
Why?
|
| Anti-Obesity Agents | 1 | 2015 | 217 | 0.400 |
Why?
|
| Behavioral Symptoms | 2 | 2013 | 175 | 0.400 |
Why?
|
| Palmitates | 1 | 2011 | 74 | 0.400 |
Why?
|
| Child Behavior | 4 | 2010 | 839 | 0.390 |
Why?
|
| Folic Acid | 2 | 2020 | 1300 | 0.390 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1620 | 0.390 |
Why?
|
| Tourette Syndrome | 13 | 1996 | 379 | 0.390 |
Why?
|
| Clonidine | 4 | 2020 | 164 | 0.390 |
Why?
|
| Pyrimidines | 5 | 2013 | 2942 | 0.390 |
Why?
|
| Food Hypersensitivity | 1 | 2018 | 622 | 0.390 |
Why?
|
| Immunologic Factors | 1 | 2020 | 1580 | 0.380 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2020 | 1953 | 0.380 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2005 | 632 | 0.370 |
Why?
|
| Young Adult | 25 | 2023 | 56430 | 0.370 |
Why?
|
| Compulsive Behavior | 2 | 2023 | 117 | 0.370 |
Why?
|
| 1-Naphthylamine | 6 | 1998 | 49 | 0.360 |
Why?
|
| Drug Administration Schedule | 13 | 2017 | 4933 | 0.360 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2008 | 322 | 0.360 |
Why?
|
| Cocaine | 10 | 1996 | 1007 | 0.360 |
Why?
|
| Delayed-Action Preparations | 4 | 2024 | 968 | 0.340 |
Why?
|
| Substance-Related Disorders | 10 | 2016 | 4258 | 0.340 |
Why?
|
| Severity of Illness Index | 24 | 2021 | 15540 | 0.340 |
Why?
|
| Developmental Disabilities | 2 | 2020 | 1456 | 0.340 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 604 | 0.330 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2010 | 211 | 0.330 |
Why?
|
| Child Behavior Disorders | 6 | 2015 | 807 | 0.330 |
Why?
|
| Gastrointestinal Diseases | 2 | 2009 | 1170 | 0.330 |
Why?
|
| Constipation | 3 | 2009 | 546 | 0.330 |
Why?
|
| Peer Group | 1 | 2013 | 635 | 0.320 |
Why?
|
| Mentors | 1 | 2013 | 631 | 0.320 |
Why?
|
| Drug Therapy, Combination | 20 | 2015 | 6489 | 0.310 |
Why?
|
| Observation | 1 | 2009 | 312 | 0.300 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2006 | 189 | 0.290 |
Why?
|
| Trazodone | 4 | 2020 | 66 | 0.290 |
Why?
|
| Depressive Disorder | 16 | 2002 | 3748 | 0.290 |
Why?
|
| Research | 2 | 2013 | 1999 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2021 | 9959 | 0.280 |
Why?
|
| Conduct Disorder | 3 | 2018 | 241 | 0.280 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2008 | 422 | 0.280 |
Why?
|
| Placebos | 13 | 2005 | 1676 | 0.280 |
Why?
|
| Lithium | 9 | 2003 | 601 | 0.280 |
Why?
|
| Indenes | 1 | 2006 | 57 | 0.270 |
Why?
|
| Propylamines | 1 | 2006 | 165 | 0.270 |
Why?
|
| Receptors, GABA | 2 | 2020 | 288 | 0.270 |
Why?
|
| Alcoholism | 1 | 2016 | 1906 | 0.260 |
Why?
|
| Prolactin | 8 | 2009 | 669 | 0.260 |
Why?
|
| Immunoglobulins | 1 | 2009 | 881 | 0.260 |
Why?
|
| Psychiatry | 2 | 2019 | 1695 | 0.260 |
Why?
|
| Electroencephalography | 2 | 2020 | 6150 | 0.260 |
Why?
|
| Cognition | 4 | 2023 | 6770 | 0.260 |
Why?
|
| Membrane Transport Proteins | 3 | 2001 | 1028 | 0.260 |
Why?
|
| Oximes | 3 | 1991 | 311 | 0.250 |
Why?
|
| Amygdala | 3 | 2018 | 1315 | 0.250 |
Why?
|
| Hospitalization | 6 | 2020 | 10262 | 0.250 |
Why?
|
| Faculty, Medical | 1 | 2013 | 1181 | 0.250 |
Why?
|
| Neopterin | 1 | 2003 | 56 | 0.230 |
Why?
|
| Psychometrics | 8 | 2015 | 3002 | 0.230 |
Why?
|
| Communication | 4 | 2021 | 3749 | 0.230 |
Why?
|
| Weight Loss | 1 | 2015 | 2622 | 0.230 |
Why?
|
| Secretin | 2 | 2000 | 57 | 0.230 |
Why?
|
| Benzodiazepines | 7 | 2009 | 1101 | 0.220 |
Why?
|
| Yohimbine | 4 | 1995 | 62 | 0.220 |
Why?
|
| Education | 3 | 2011 | 543 | 0.220 |
Why?
|
| Hydroxyindoleacetic Acid | 3 | 1998 | 90 | 0.220 |
Why?
|
| Norepinephrine | 4 | 1996 | 909 | 0.220 |
Why?
|
| Lorazepam | 1 | 2023 | 145 | 0.220 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 3 | 2018 | 304 | 0.220 |
Why?
|
| Clinical Trials as Topic | 7 | 2009 | 7913 | 0.210 |
Why?
|
| Borderline Personality Disorder | 1 | 2010 | 736 | 0.210 |
Why?
|
| Priapism | 1 | 2002 | 31 | 0.210 |
Why?
|
| Anticonvulsants | 4 | 2024 | 1916 | 0.210 |
Why?
|
| Depressive Disorder, Major | 3 | 2018 | 4644 | 0.210 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2006 | 1004 | 0.210 |
Why?
|
| Paroxetine | 4 | 1999 | 182 | 0.200 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 2219 | 0.200 |
Why?
|
| Nerve Tissue Proteins | 4 | 2012 | 4462 | 0.200 |
Why?
|
| Valproic Acid | 1 | 2024 | 445 | 0.200 |
Why?
|
| Obsessive Behavior | 1 | 2021 | 47 | 0.190 |
Why?
|
| Mianserin | 1 | 2001 | 52 | 0.190 |
Why?
|
| Hyperkinesis | 2 | 2015 | 89 | 0.190 |
Why?
|
| Corticotropin-Releasing Hormone | 5 | 2007 | 369 | 0.190 |
Why?
|
| Receptors, Serotonin | 5 | 2002 | 201 | 0.190 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 2020 | 17 | 0.190 |
Why?
|
| Antidepressive Agents | 7 | 2005 | 2838 | 0.190 |
Why?
|
| Folate Receptor 1 | 1 | 2020 | 36 | 0.190 |
Why?
|
| Personality Inventory | 7 | 2005 | 1030 | 0.190 |
Why?
|
| Membrane Glycoproteins | 4 | 2019 | 3768 | 0.190 |
Why?
|
| Haloperidol | 4 | 1997 | 397 | 0.190 |
Why?
|
| Dopamine | 7 | 2008 | 1591 | 0.180 |
Why?
|
| alpha-Methyltyrosine | 1 | 1999 | 6 | 0.180 |
Why?
|
| Dyskinesia, Drug-Induced | 3 | 2008 | 163 | 0.180 |
Why?
|
| Biogenic Monoamines | 2 | 2013 | 50 | 0.180 |
Why?
|
| Folic Acid Deficiency | 1 | 2020 | 115 | 0.170 |
Why?
|
| Leukocyte Count | 1 | 2003 | 1588 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 323 | 0.170 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2015 | 1107 | 0.170 |
Why?
|
| Prednisolone | 1 | 2020 | 334 | 0.170 |
Why?
|
| Adaptation, Psychological | 4 | 2019 | 2576 | 0.170 |
Why?
|
| Combat Disorders | 2 | 1991 | 302 | 0.170 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 514 | 0.160 |
Why?
|
| Methoxyhydroxyphenylglycol | 5 | 1995 | 93 | 0.160 |
Why?
|
| Affect | 13 | 2003 | 1476 | 0.160 |
Why?
|
| Caregivers | 4 | 2021 | 2094 | 0.160 |
Why?
|
| Models, Biological | 1 | 2015 | 9583 | 0.160 |
Why?
|
| Receptors, Dopamine | 3 | 2000 | 295 | 0.160 |
Why?
|
| Leucovorin | 1 | 2020 | 628 | 0.160 |
Why?
|
| Catecholamines | 1 | 1999 | 387 | 0.160 |
Why?
|
| Dopamine Agents | 2 | 1997 | 189 | 0.160 |
Why?
|
| Retrospective Studies | 17 | 2024 | 77449 | 0.160 |
Why?
|
| Dexamethasone | 1 | 2005 | 1951 | 0.160 |
Why?
|
| Neuroimmunomodulation | 1 | 2019 | 157 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2005 | 2107 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 820 | 0.160 |
Why?
|
| Drug Resistance | 5 | 2013 | 1609 | 0.150 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2019 | 172 | 0.150 |
Why?
|
| Neuropeptides | 2 | 2005 | 942 | 0.150 |
Why?
|
| Desipramine | 4 | 2000 | 184 | 0.150 |
Why?
|
| Thinking | 1 | 2000 | 319 | 0.150 |
Why?
|
| Single-Blind Method | 5 | 2014 | 1590 | 0.150 |
Why?
|
| Bone Density | 4 | 2018 | 3468 | 0.150 |
Why?
|
| Serotonin Agents | 1 | 1997 | 29 | 0.150 |
Why?
|
| Prevalence | 4 | 2022 | 15226 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 1524 | 0.150 |
Why?
|
| Schizophrenia, Childhood | 1 | 1996 | 6 | 0.140 |
Why?
|
| Behavior, Animal | 4 | 2019 | 1881 | 0.140 |
Why?
|
| Schizophrenic Psychology | 3 | 2009 | 1678 | 0.140 |
Why?
|
| Treatment Failure | 6 | 2021 | 2618 | 0.140 |
Why?
|
| Prospective Studies | 14 | 2013 | 53288 | 0.140 |
Why?
|
| Administration, Intranasal | 6 | 2021 | 446 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 1519 | 0.140 |
Why?
|
| Interferon-gamma | 2 | 2004 | 3206 | 0.140 |
Why?
|
| Bone and Bones | 2 | 2017 | 2575 | 0.130 |
Why?
|
| Middle Aged | 48 | 2019 | 213383 | 0.130 |
Why?
|
| Parent-Child Relations | 3 | 2012 | 747 | 0.130 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2016 | 146 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 1401 | 0.130 |
Why?
|
| Pregnancy | 10 | 2024 | 29144 | 0.130 |
Why?
|
| Body Weight | 5 | 2013 | 4669 | 0.130 |
Why?
|
| Microglia | 1 | 2023 | 1266 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 441 | 0.130 |
Why?
|
| Interferon Inducers | 1 | 2014 | 25 | 0.130 |
Why?
|
| Glutamates | 2 | 2008 | 398 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2000 | 494 | 0.130 |
Why?
|
| Brain Chemistry | 2 | 1998 | 981 | 0.130 |
Why?
|
| Gene Dosage | 2 | 2010 | 1252 | 0.130 |
Why?
|
| Nitric Oxide | 1 | 2004 | 2132 | 0.130 |
Why?
|
| Cannabis | 1 | 2021 | 439 | 0.130 |
Why?
|
| Nutritional Status | 2 | 2018 | 1609 | 0.130 |
Why?
|
| Personality Assessment | 5 | 2009 | 647 | 0.120 |
Why?
|
| Schizophrenia | 4 | 2015 | 6882 | 0.120 |
Why?
|
| Psychomotor Performance | 3 | 2015 | 1901 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2013 | 17446 | 0.120 |
Why?
|
| Syndrome | 1 | 2020 | 3251 | 0.120 |
Why?
|
| Sertraline | 6 | 1998 | 206 | 0.120 |
Why?
|
| Combined Modality Therapy | 8 | 2012 | 8642 | 0.120 |
Why?
|
| Monocytes | 1 | 2003 | 2596 | 0.120 |
Why?
|
| Alcoholic Intoxication | 1 | 1995 | 188 | 0.120 |
Why?
|
| Immune System | 1 | 2019 | 805 | 0.110 |
Why?
|
| Immunity | 1 | 2019 | 1012 | 0.110 |
Why?
|
| Animals | 18 | 2023 | 168757 | 0.110 |
Why?
|
| Inflammation | 3 | 2019 | 10638 | 0.110 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 6234 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 1677 | 0.110 |
Why?
|
| Disorders of Excessive Somnolence | 3 | 2008 | 271 | 0.110 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 2147 | 0.110 |
Why?
|
| Factor Analysis, Statistical | 3 | 2015 | 977 | 0.110 |
Why?
|
| Maternal Exposure | 1 | 2019 | 961 | 0.110 |
Why?
|
| Biogenic Amines | 3 | 1999 | 50 | 0.110 |
Why?
|
| MEDLINE | 1 | 2012 | 125 | 0.110 |
Why?
|
| Genetic Linkage | 1 | 1998 | 2421 | 0.110 |
Why?
|
| Cross-Over Studies | 5 | 2016 | 2029 | 0.110 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 581 | 0.110 |
Why?
|
| Serotonin Receptor Agonists | 4 | 1997 | 152 | 0.100 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2016 | 372 | 0.100 |
Why?
|
| Diagnostic Errors | 2 | 2013 | 1257 | 0.100 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 18029 | 0.100 |
Why?
|
| Facial Expression | 1 | 2016 | 508 | 0.100 |
Why?
|
| Research Personnel | 2 | 2008 | 573 | 0.100 |
Why?
|
| Speech | 1 | 2017 | 540 | 0.100 |
Why?
|
| Synaptic Transmission | 1 | 2018 | 1178 | 0.100 |
Why?
|
| Fetus | 1 | 2019 | 1880 | 0.100 |
Why?
|
| Ethanol | 2 | 1995 | 1342 | 0.100 |
Why?
|
| Risk Factors | 7 | 2021 | 72290 | 0.100 |
Why?
|
| Encephalitis | 1 | 2014 | 423 | 0.100 |
Why?
|
| Implosive Therapy | 1 | 2012 | 120 | 0.100 |
Why?
|
| Social Adjustment | 2 | 2012 | 631 | 0.100 |
Why?
|
| Melatonin | 4 | 2020 | 721 | 0.100 |
Why?
|
| Language | 1 | 2020 | 1471 | 0.090 |
Why?
|
| Linear Models | 3 | 2017 | 5952 | 0.090 |
Why?
|
| Carrier Proteins | 3 | 2001 | 5021 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2008 | 1121 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2016 | 921 | 0.090 |
Why?
|
| Analysis of Variance | 8 | 2014 | 6365 | 0.090 |
Why?
|
| Learning | 2 | 2017 | 1713 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 35421 | 0.090 |
Why?
|
| Phenotype | 2 | 2020 | 16365 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2023 | 12959 | 0.090 |
Why?
|
| Electrocardiography | 3 | 2016 | 6442 | 0.090 |
Why?
|
| Impulsive Behavior | 2 | 2004 | 316 | 0.090 |
Why?
|
| Infant | 5 | 2013 | 35136 | 0.090 |
Why?
|
| Ketoconazole | 3 | 1999 | 95 | 0.090 |
Why?
|
| Genome-Wide Association Study | 4 | 2012 | 12261 | 0.090 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2010 | 162 | 0.080 |
Why?
|
| Verbal Behavior | 1 | 2010 | 339 | 0.080 |
Why?
|
| Social Perception | 1 | 2013 | 425 | 0.080 |
Why?
|
| Case-Control Studies | 9 | 2018 | 21746 | 0.080 |
Why?
|
| Reproductive History | 1 | 2010 | 209 | 0.080 |
Why?
|
| Language Therapy | 1 | 2008 | 25 | 0.080 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2014 | 1121 | 0.080 |
Why?
|
| Epidermal Growth Factor | 1 | 2011 | 708 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 1439 | 0.080 |
Why?
|
| Breast Feeding | 1 | 1997 | 1338 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2011 | 651 | 0.080 |
Why?
|
| Quality of Life | 2 | 2021 | 12804 | 0.080 |
Why?
|
| Adolescent Behavior | 1 | 1997 | 1151 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 3798 | 0.080 |
Why?
|
| Social Control, Informal | 1 | 2008 | 46 | 0.080 |
Why?
|
| Health Education | 1 | 2015 | 1056 | 0.080 |
Why?
|
| Animal Experimentation | 1 | 2008 | 45 | 0.080 |
Why?
|
| Dissociative Disorders | 1 | 1990 | 231 | 0.080 |
Why?
|
| Self Report | 1 | 2019 | 3558 | 0.080 |
Why?
|
| Body Mass Index | 5 | 2015 | 12720 | 0.080 |
Why?
|
| Observer Variation | 3 | 2009 | 2593 | 0.080 |
Why?
|
| Self Mutilation | 1 | 2008 | 58 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 14722 | 0.080 |
Why?
|
| DNA Copy Number Variations | 3 | 2011 | 1941 | 0.080 |
Why?
|
| Catheters, Indwelling | 3 | 2004 | 426 | 0.080 |
Why?
|
| Reproducibility of Results | 10 | 2016 | 19905 | 0.080 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2004 | 503 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2014 | 1790 | 0.080 |
Why?
|
| Puerperal Disorders | 1 | 2010 | 275 | 0.080 |
Why?
|
| Veterans | 2 | 1991 | 2519 | 0.070 |
Why?
|
| Iron | 1 | 2015 | 1774 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2016 | 3913 | 0.070 |
Why?
|
| Hydrocortisone | 7 | 1997 | 1826 | 0.070 |
Why?
|
| Arginine Vasopressin | 2 | 1999 | 130 | 0.070 |
Why?
|
| Internet | 1 | 2019 | 3064 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2019 | 2958 | 0.070 |
Why?
|
| Mood Disorders | 2 | 2018 | 1106 | 0.070 |
Why?
|
| Neural Pathways | 3 | 2015 | 2972 | 0.070 |
Why?
|
| Psychotherapy | 3 | 2004 | 1643 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3528 | 0.070 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2007 | 147 | 0.070 |
Why?
|
| Genetic Variation | 3 | 2010 | 6544 | 0.070 |
Why?
|
| Glycols | 1 | 1985 | 59 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2010 | 187 | 0.070 |
Why?
|
| Terrorism | 1 | 2008 | 211 | 0.060 |
Why?
|
| Neurochemistry | 1 | 2005 | 29 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15076 | 0.060 |
Why?
|
| Haplotypes | 1 | 2011 | 2779 | 0.060 |
Why?
|
| Drug Design | 1 | 2010 | 1076 | 0.060 |
Why?
|
| Time Factors | 9 | 2015 | 40075 | 0.060 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2006 | 303 | 0.060 |
Why?
|
| Schizotypal Personality Disorder | 2 | 2000 | 288 | 0.060 |
Why?
|
| Growth Hormone | 4 | 1997 | 705 | 0.060 |
Why?
|
| Emotions | 1 | 2016 | 2661 | 0.060 |
Why?
|
| Gonadal Hormones | 1 | 2023 | 29 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2009 | 852 | 0.060 |
Why?
|
| Awareness | 1 | 2008 | 640 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2010 | 941 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 1622 | 0.060 |
Why?
|
| Nitrites | 1 | 2004 | 160 | 0.060 |
Why?
|
| Neurosecretory Systems | 2 | 1998 | 231 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 1995 | 174 | 0.060 |
Why?
|
| Genotype | 6 | 2012 | 12951 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2022 | 40561 | 0.060 |
Why?
|
| Research Design | 5 | 2013 | 5987 | 0.060 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2009 | 445 | 0.060 |
Why?
|
| Cognition Disorders | 3 | 2008 | 4043 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 3508 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 356 | 0.060 |
Why?
|
| Attitude to Health | 3 | 2016 | 2052 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2015 | 1947 | 0.050 |
Why?
|
| Interview, Psychological | 1 | 2006 | 812 | 0.050 |
Why?
|
| Neural Inhibition | 1 | 2007 | 602 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2019 | 4558 | 0.050 |
Why?
|
| Nitrates | 1 | 2004 | 265 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 552 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4468 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5137 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2278 | 0.050 |
Why?
|
| Premature Birth | 1 | 2014 | 1721 | 0.050 |
Why?
|
| Fenfluramine | 3 | 1997 | 59 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2010 | 1774 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 3760 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2016 | 3864 | 0.050 |
Why?
|
| Family | 3 | 2021 | 3147 | 0.050 |
Why?
|
| Hypertension | 1 | 2022 | 8480 | 0.050 |
Why?
|
| Movement Disorders | 1 | 2005 | 445 | 0.050 |
Why?
|
| Tryptophan Oxygenase | 1 | 2001 | 19 | 0.050 |
Why?
|
| Age of Onset | 3 | 2010 | 3271 | 0.050 |
Why?
|
| Language Development | 2 | 2013 | 187 | 0.050 |
Why?
|
| Electroconvulsive Therapy | 2 | 1993 | 477 | 0.050 |
Why?
|
| Leptin | 2 | 2013 | 1599 | 0.050 |
Why?
|
| Circadian Rhythm | 4 | 2019 | 2624 | 0.050 |
Why?
|
| Diarrhea | 1 | 2008 | 1348 | 0.050 |
Why?
|
| Acute Disease | 3 | 2010 | 7149 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2003 | 346 | 0.050 |
Why?
|
| Neuropsychological Tests | 4 | 2015 | 6993 | 0.050 |
Why?
|
| Absorptiometry, Photon | 2 | 2018 | 1725 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2012 | 15519 | 0.050 |
Why?
|
| Planning Techniques | 1 | 2001 | 82 | 0.050 |
Why?
|
| Hippocampus | 1 | 2013 | 3675 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2021 | 379 | 0.050 |
Why?
|
| Nausea | 1 | 2024 | 673 | 0.050 |
Why?
|
| Adrenergic Antagonists | 1 | 2000 | 24 | 0.050 |
Why?
|
| Diet | 5 | 2018 | 7939 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 1344 | 0.050 |
Why?
|
| Infusions, Intravenous | 5 | 1998 | 2274 | 0.050 |
Why?
|
| Endpoint Determination | 2 | 2019 | 601 | 0.050 |
Why?
|
| Stem Cells | 1 | 2013 | 3567 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2004 | 1263 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 2216 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1999 | 648 | 0.040 |
Why?
|
| Language Development Disorders | 2 | 2014 | 196 | 0.040 |
Why?
|
| Binding Sites | 1 | 2008 | 6114 | 0.040 |
Why?
|
| Family Health | 1 | 2004 | 1282 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2007 | 1827 | 0.040 |
Why?
|
| Genome, Human | 2 | 2010 | 4420 | 0.040 |
Why?
|
| Grooming | 1 | 1999 | 37 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2019 | 53 | 0.040 |
Why?
|
| Behavior | 2 | 1993 | 561 | 0.040 |
Why?
|
| Opioid Peptides | 1 | 1999 | 42 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 3647 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 658 | 0.040 |
Why?
|
| Appetite | 1 | 2001 | 243 | 0.040 |
Why?
|
| Naltrexone | 1 | 2001 | 307 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 789 | 0.040 |
Why?
|
| Interneurons | 2 | 2018 | 577 | 0.040 |
Why?
|
| Alleles | 3 | 2012 | 6933 | 0.040 |
Why?
|
| Receptors, Vasopressin | 1 | 1999 | 112 | 0.040 |
Why?
|
| Gynecomastia | 1 | 1999 | 88 | 0.040 |
Why?
|
| Receptors, Neuropeptide | 1 | 1999 | 111 | 0.040 |
Why?
|
| Age Factors | 5 | 2004 | 18370 | 0.040 |
Why?
|
| Medication Errors | 1 | 2004 | 798 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 1144 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 539 | 0.040 |
Why?
|
| Body Temperature | 2 | 2017 | 777 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2001 | 542 | 0.040 |
Why?
|
| Poly I-C | 1 | 2017 | 115 | 0.040 |
Why?
|
| Avoidance Learning | 1 | 1999 | 233 | 0.040 |
Why?
|
| Hormone Antagonists | 1 | 1997 | 108 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2015 | 9849 | 0.040 |
Why?
|
| Drinking | 1 | 1998 | 197 | 0.040 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 1889 | 0.040 |
Why?
|
| Amino Acids, Essential | 1 | 1996 | 24 | 0.040 |
Why?
|
| Histone Deacetylases | 1 | 2021 | 728 | 0.040 |
Why?
|
| Retreatment | 1 | 1998 | 610 | 0.040 |
Why?
|
| Somatostatin | 1 | 1999 | 459 | 0.040 |
Why?
|
| Anger | 2 | 2016 | 402 | 0.040 |
Why?
|
| Comet Assay | 1 | 2016 | 71 | 0.030 |
Why?
|
| Sex Factors | 4 | 2019 | 10397 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3870 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 1996 | 1420 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 2861 | 0.030 |
Why?
|
| Homovanillic Acid | 2 | 1992 | 75 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 1991 | 4266 | 0.030 |
Why?
|
| Attention | 1 | 2006 | 2400 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 21827 | 0.030 |
Why?
|
| Enuresis | 1 | 2015 | 47 | 0.030 |
Why?
|
| Mice | 5 | 2023 | 81183 | 0.030 |
Why?
|
| Iron Metabolism Disorders | 1 | 2015 | 27 | 0.030 |
Why?
|
| Endoscopy | 1 | 2005 | 1785 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2000 | 562 | 0.030 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 2 | 1992 | 37 | 0.030 |
Why?
|
| Patient Participation | 1 | 2005 | 1457 | 0.030 |
Why?
|
| Checklist | 2 | 2013 | 833 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2012 | 7880 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2016 | 216 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 39050 | 0.030 |
Why?
|
| Activities of Daily Living | 3 | 2016 | 2418 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 1995 | 235 | 0.030 |
Why?
|
| Happiness | 1 | 2016 | 170 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 128 | 0.030 |
Why?
|
| Dynorphins | 1 | 1994 | 84 | 0.030 |
Why?
|
| Insufflation | 1 | 1994 | 65 | 0.030 |
Why?
|
| Cytokines | 2 | 2019 | 7322 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2002 | 1670 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3843 | 0.030 |
Why?
|
| Antimanic Agents | 1 | 1997 | 522 | 0.030 |
Why?
|
| Tyrosine | 1 | 1998 | 1461 | 0.030 |
Why?
|
| Arousal | 3 | 1996 | 1165 | 0.030 |
Why?
|
| Amino Acids | 3 | 1997 | 1736 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2018 | 1173 | 0.030 |
Why?
|
| Radius | 1 | 2017 | 422 | 0.030 |
Why?
|
| Panic Disorder | 2 | 1994 | 616 | 0.030 |
Why?
|
| Recurrence | 1 | 2005 | 8340 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 589 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2004 | 4199 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 1995 | 302 | 0.030 |
Why?
|
| Europe | 2 | 2010 | 3339 | 0.030 |
Why?
|
| Ferritins | 1 | 2015 | 590 | 0.030 |
Why?
|
| Obesity | 2 | 2022 | 12745 | 0.030 |
Why?
|
| Child Development | 1 | 2004 | 2223 | 0.030 |
Why?
|
| Carbidopa | 1 | 1992 | 31 | 0.030 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2013 | 129 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2003 | 5974 | 0.030 |
Why?
|
| Homocysteine | 1 | 2016 | 647 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2002 | 3200 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2014 | 505 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 4328 | 0.030 |
Why?
|
| Amidohydrolases | 1 | 2013 | 169 | 0.030 |
Why?
|
| Depression, Postpartum | 1 | 1997 | 340 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2008 | 3309 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2013 | 143 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4420 | 0.030 |
Why?
|
| Dioxanes | 1 | 1992 | 37 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2016 | 502 | 0.030 |
Why?
|
| Aged | 6 | 2019 | 163280 | 0.030 |
Why?
|
| Heroin Dependence | 1 | 1993 | 175 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 2726 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2020 | 2035 | 0.030 |
Why?
|
| Phenelzine | 1 | 1991 | 28 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1995 | 1032 | 0.030 |
Why?
|
| Fasting | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Socialization | 1 | 2011 | 87 | 0.030 |
Why?
|
| Levodopa | 1 | 1992 | 219 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2004 | 703 | 0.020 |
Why?
|
| Imipramine | 1 | 1991 | 97 | 0.020 |
Why?
|
| Baclofen | 1 | 1992 | 129 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2015 | 647 | 0.020 |
Why?
|
| Overweight | 1 | 2022 | 2371 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 1993 | 312 | 0.020 |
Why?
|
| Tibia | 1 | 2017 | 1077 | 0.020 |
Why?
|
| United States | 4 | 2022 | 69872 | 0.020 |
Why?
|
| Seasons | 1 | 1996 | 1493 | 0.020 |
Why?
|
| Stress, Psychological | 2 | 2004 | 4245 | 0.020 |
Why?
|
| Mitochondria | 1 | 2023 | 3520 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2187 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2011 | 318 | 0.020 |
Why?
|
| Exercise | 2 | 2017 | 5615 | 0.020 |
Why?
|
| Patient Admission | 1 | 1998 | 1380 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 6171 | 0.020 |
Why?
|
| Neurons | 1 | 2009 | 9338 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2010 | 210 | 0.020 |
Why?
|
| Premenstrual Syndrome | 1 | 2010 | 109 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2011 | 389 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1861 | 0.020 |
Why?
|
| Methadone | 1 | 1992 | 306 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2022 | 2494 | 0.020 |
Why?
|
| Vietnam | 1 | 1990 | 408 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 1995 | 1221 | 0.020 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2009 | 108 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 1999 | 2057 | 0.020 |
Why?
|
| Blood Pressure | 5 | 1996 | 8554 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 975 | 0.020 |
Why?
|
| Memory | 1 | 1999 | 2174 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 13989 | 0.020 |
Why?
|
| Inpatients | 1 | 2020 | 2518 | 0.020 |
Why?
|
| Biopsy | 1 | 2001 | 6756 | 0.020 |
Why?
|
| Animal Rights | 1 | 2008 | 10 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2023 | 4286 | 0.020 |
Why?
|
| Piperidines | 2 | 1994 | 1602 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1995 | 1547 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 2 | 2004 | 553 | 0.020 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2009 | 265 | 0.020 |
Why?
|
| Rats | 2 | 2007 | 24260 | 0.020 |
Why?
|
| Urocortins | 1 | 2007 | 19 | 0.020 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2007 | 27 | 0.020 |
Why?
|
| Menarche | 1 | 2010 | 516 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2009 | 528 | 0.020 |
Why?
|
| Motor Activity | 1 | 2017 | 2714 | 0.020 |
Why?
|
| Reference Values | 3 | 2004 | 4982 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 5751 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1992 | 1959 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1785 | 0.020 |
Why?
|
| Crime | 1 | 2008 | 215 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8663 | 0.020 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2007 | 87 | 0.020 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2007 | 129 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1997 | 0.020 |
Why?
|
| Parental Consent | 1 | 2006 | 62 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7799 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2008 | 191 | 0.020 |
Why?
|
| Chronic Disease | 2 | 1999 | 9146 | 0.020 |
Why?
|
| Parturition | 1 | 2010 | 441 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2014 | 944 | 0.020 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2007 | 154 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 2432 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 2026 | 0.020 |
Why?
|
| Permissiveness | 1 | 2005 | 2 | 0.020 |
Why?
|
| Primates | 1 | 2008 | 545 | 0.020 |
Why?
|
| Drug Interactions | 3 | 1996 | 1460 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 3588 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 2703 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2002 | 1792 | 0.020 |
Why?
|
| Diet Records | 1 | 2006 | 425 | 0.020 |
Why?
|
| Depression, Chemical | 2 | 1995 | 191 | 0.020 |
Why?
|
| Buprenorphine | 1 | 1993 | 640 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3086 | 0.020 |
Why?
|
| Drug Tolerance | 2 | 1997 | 376 | 0.020 |
Why?
|
| Clonazepam | 2 | 1996 | 136 | 0.020 |
Why?
|
| Aging | 1 | 2004 | 8664 | 0.020 |
Why?
|
| Calcium | 1 | 2018 | 5756 | 0.020 |
Why?
|
| Homeostasis | 1 | 2015 | 3340 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 1504 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 2715 | 0.020 |
Why?
|
| Pulse | 2 | 1996 | 229 | 0.020 |
Why?
|
| Vitamin D | 1 | 2018 | 3223 | 0.010 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2006 | 475 | 0.010 |
Why?
|
| Psychoneuroimmunology | 1 | 2002 | 13 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2010 | 1783 | 0.010 |
Why?
|
| Euphoria | 2 | 1993 | 67 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2007 | 1901 | 0.010 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2002 | 63 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2005 | 469 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1995 | 3966 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2014 | 5097 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2005 | 607 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2022 | 25625 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1656 | 0.010 |
Why?
|
| Outpatients | 1 | 2008 | 1486 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 475 | 0.010 |
Why?
|
| Kynurenine | 1 | 2001 | 139 | 0.010 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2001 | 109 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1991 | 2731 | 0.010 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 1708 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 1997 | 5027 | 0.010 |
Why?
|
| Ambulatory Care | 3 | 1999 | 2708 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 1660 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 11725 | 0.010 |
Why?
|
| Life Change Events | 1 | 2004 | 938 | 0.010 |
Why?
|
| Medication Adherence | 1 | 2010 | 2063 | 0.010 |
Why?
|
| Depression | 2 | 1995 | 7766 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2008 | 2684 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 3772 | 0.010 |
Why?
|
| Proteins | 1 | 2013 | 6103 | 0.010 |
Why?
|
| Cell Movement | 1 | 2010 | 5217 | 0.010 |
Why?
|
| Rehabilitation, Vocational | 1 | 1998 | 82 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 20129 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2001 | 895 | 0.010 |
Why?
|
| Opioid-Related Disorders | 1 | 1992 | 2065 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25043 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1738 | 0.010 |
Why?
|
| Neurophysins | 1 | 1994 | 14 | 0.010 |
Why?
|
| Hormones | 1 | 1998 | 889 | 0.010 |
Why?
|
| Feedback | 1 | 1997 | 795 | 0.010 |
Why?
|
| Defense Mechanisms | 1 | 1994 | 178 | 0.010 |
Why?
|
| Heart Rate | 2 | 1996 | 4091 | 0.010 |
Why?
|
| Idazoxan | 1 | 1992 | 9 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11366 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 1997 | 683 | 0.010 |
Why?
|
| Internal-External Control | 1 | 1994 | 363 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1996 | 1572 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 3923 | 0.010 |
Why?
|
| Pineal Gland | 1 | 1993 | 166 | 0.010 |
Why?
|
| Half-Life | 1 | 1993 | 661 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 29786 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 6622 | 0.010 |
Why?
|
| Decision Trees | 1 | 1993 | 506 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2001 | 1591 | 0.010 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 1992 | 168 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1996 | 1681 | 0.010 |
Why?
|
| Phototherapy | 1 | 1993 | 377 | 0.010 |
Why?
|
| AIDS Dementia Complex | 1 | 1991 | 154 | 0.010 |
Why?
|
| Epinephrine | 1 | 1993 | 792 | 0.010 |
Why?
|
| Mental Recall | 1 | 1995 | 1205 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1992 | 930 | 0.010 |
Why?
|
| Hypothalamus | 1 | 1994 | 1063 | 0.000 |
Why?
|
| Self Concept | 1 | 1994 | 1025 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2010 | 23403 | 0.000 |
Why?
|
| Sleep Deprivation | 1 | 1993 | 832 | 0.000 |
Why?
|
| Pyrazines | 1 | 1992 | 1230 | 0.000 |
Why?
|
| HIV Infections | 1 | 1991 | 16718 | 0.000 |
Why?
|
| Brain Mapping | 1 | 1994 | 6669 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1996 | 23338 | 0.000 |
Why?
|